News Novel drug to tackle inflammatory diseases begins trial An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator.
News Chi-Med agrees R&D partnership with Inmagene China’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment of several immunological diseases.
News MSD's Sac-TMT delivers in first phase 3 readout MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
